Program
amlitelimab
Also written as “Amlitelimab”, “KY1005” and “SAR445229”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Immune System Diseases · Celiac Disease · Alopecia Areata, led by Sanofi.
Furthest: phase 3, since Aug 5, 202219 company-led studies, 5 open or runningNext primary completion: Sep 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 195 open or running | phase 3since Aug 5, 2022 | May 11, 2017 | Sep 30, 2027phase 3 · NCT06241118 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since May 11, 2017.
- Aug 5, 2022Phase 3 study in Dermatitis, AtopicNCT05492578 · 1,856 enrolled · United States, Argentina, Australia and more
- Mar 3, 2023Phase 2 study in Dermatitis, AtopicNCT05769777 · 999 enrolled · United States, Argentina, Australia and more
- Aug 23, 2023Phase 2 study in Dermatitis, AtopicNCT06015308 · 224 enrolled · United States, Canada
- Sep 5, 2023Phase 2 study in AsthmaNCT06033833 · 335 enrolled · United States, Argentina, Brazil and more
- Oct 31, 2023Phase 2 study in HidradenitisNCT06118099 · 90 enrolled · United States, Australia, Canada and more
- Nov 8, 2023Phase 3 study in Dermatitis, AtopicNCT06130566 · 601 enrolled · United States, Argentina, Australia and more
- Dec 13, 2023Phase 3 study in Dermatitis, AtopicNCT06181435 · 589 enrolled · United States, Argentina, Bulgaria and more
- Jan 16, 20242 phase 3 studies in Dermatitis, AtopicNCT06224348, NCT06241118
- May 6, 2024Phase 3 study in Dermatitis, AtopicNCT06407934 · 1,541 enrolled · United States, Argentina, Australia and more
- May 31, 2024Phase 2 study in Alopecia AreataNCT06444451 · 166 enrolled · United States, Argentina, Australia and more
- Aug 14, 2024Phase 2 study in Celiac DiseaseNCT06557772 · 229 enrolled · United States, Argentina, Australia and more
- Nov 11, 2024Phase 1 study in Dermatitis, AtopicNCT06686628 · 23 enrolled · Germany
- Aug 21, 2025Phase 1 study in Healthy VolunteersNCT07146750 · 212 enrolled · United States
- Oct 2, 2026Phase 2 study terminatedStudy stoppedNCT06033833 · “Sponsor decision; the decision is not related to any safety concern.”
Ahead
- Sep 30, 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06241118
- Jan 22, 2029Primary completion: phase 3 study in Dermatitis, AtopicNCT05492578
- Jun 11, 2031Primary completion: phase 2 study in Dermatitis, AtopicNCT05769777
TargetBeta
TNFSF4 →read by rule
“Tumor necrosis factor ligand superfamily member 4 inhibitor”ChEMBL 37, by rule
Other programs on TNFSF4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brivekimig | Sanofi | phase 2 | 6 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07146750Healthy Volunteers · United States | 1 | Completed | Apr 8, 2026 | 212 |
| NCT06686628Dermatitis, Atopic · Germany | 1 | Completed | Nov 21, 2025 | 23 |
| NCT06557772Celiac Disease · United States, Argentina, Australia and more | 2 | Active, not recruiting | Aug 5, 2026 | 229 |
| NCT06444451Alopecia Areata · United States, Argentina, Australia and more | 2 | Terminated | Sep 24, 2025 | 166 |
| NCT06407934Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 10, 2026 | 1,541 |
| NCT06241118Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 30, 2027 | 464 |
| NCT06224348Dermatitis, Atopic · United States, Argentina, Brazil and more | 3 | Completed | Aug 21, 2025 | 643 |
| NCT06181435Dermatitis, Atopic · United States, Argentina, Bulgaria and more | 3 | Completed | Nov 25, 2025 | 589 |
| NCT06130566Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Completed | Jul 23, 2025 | 601 |
| NCT06118099Hidradenitis · United States, Australia, Canada and more | 2 | Terminated | Feb 6, 2025 | 90 |
| NCT06033833Asthma · United States, Argentina, Brazil and more | 2 | Terminated | Sep 22, 2026 | 335 |
| NCT06015308Dermatitis, Atopic · United States, Canada | 2 | Completed | Oct 1, 2025 | 224 |
| NCT05769777Dermatitis, Atopic · United States, Argentina, Australia and more | 2 | Active, not recruiting | Jun 11, 2031 | 999 |
| NCT05492578Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 22, 2029 | 1,856 |
| NCT05421598Asthma · United States, Argentina, Brazil and more | 2 | Completed | Oct 11, 2024 | 437 |
| NCT05131477Eczema · United States, Australia, Bulgaria and more | 2 | Completed | Apr 26, 2023 | 390 |
| NCT04449939Immune System Diseases · United Kingdom | 1 | Completed | Nov 30, 2020 | 24 |
| NCT03754309Dermatitis, Atopic · Germany, Poland, Spain and more | 2 | Completed | May 12, 2020 | 89 |
| NCT03161288Immune System Diseases · Netherlands | 1 | Completed | Mar 30, 2018 | 64 |
How it is read
Names in the registry
- “Amlitelimab”, 15 entries
- “KY1005”, 3 entries
- “SAR445229”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 10 studies
- Asthma, 2 studies
- Immune System Diseases, 2 studies
- Celiac Disease, 1 study
- Alopecia Areata, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.